29 Oct 2022 , 11:07 AM
Revenue increase was 20.9% in sequential terms. In terms of verticals, global generics saw 18% growth at Rs5,595 crore while pharma services and API fell -19% at Rs811 crore.
The R&D expenses in the quarter at Rs487 crore accounted for 7.7% of revenues, well above industry average. Within global generics, North America grew at 48% while Europe and India revenues were flat yoy.
North America accounted for 44% of revenues followed by EMs at 19% and Indian markets at 18%.
EBITDA came in at Rs1,932 crore with EBITDA margins at 30.6% for the quarter. Gross profit margins stood at 59.1% with the global generics segment enjoying 65% gross margins.
Capex is estimated at Rs250 crore for the quarter while the net debt to equity stands at 0.07X. Net profit margins at 17.65% in Q2FY23 is higher compared to 17.21% in Q1FY22 but lower than 22.77% in Q1FY23.
Financial highlights for Sep-22 compared yoy and sequentially
Dr Reddy’s Labs | |||||
Rs in Crore | Sep-22 | Sep-21 | YOY | Jun-22 | QOQ |
Total Income (Rs cr) | ₹ 6,305.70 | ₹ 5,763.20 | 9.41% | ₹ 5,215.40 | 20.91% |
Net Profit (Rs cr) | ₹ 1,112.80 | ₹ 992.00 | 12.18% | ₹ 1,187.60 | -6.30% |
Diluted EPS (Rs) | ₹ 66.89 | ₹ 59.65 | ₹ 71.40 | ||
Net Margins | 17.65% | 17.21% | 22.77% |
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.